---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Cost-effectiveness evidence"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Cost-effectiveness evidence. Topics: Remibrutinib list price per 30-day supply, January 2026; Dupilumab wholesale acquisition cost per 4-week supply, January 2026; Omalizumab annual list price range; Omalizumab unit wholesale acquisition cost at the end of 2025 and annual increase since 2019; 15 further topics. 20 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics/cost-effectiveness"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Cost-effectiveness evidence

<a id="heading-4.1"></a>

## 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

### Summary

- Barzolvolimab has no published price and no budget impact model; a BLA submission is anticipated in 2027.
- Comparator prices: remibrutinib $4,521 per 30-day supply (60 tablets) as of January 7, 2026; dupilumab $4,193.03 per 4-week supply as of January 1, 2026; omalizumab approximately $30,000 - $60,000 annually at list price (WAC) per Genentech and approximately $1472.76 per unit at the end of 2025 per the Oregon PDAB review. The Oregon PDAB review lists 2025 WACs per 30-day supply of $5,891 for omalizumab 600 mg every 1 month and $3,993 for dupilumab 300 mg every 2 weeks.
- Omalizumab biosimilar competition became available in 2026, and a negotiated Medicare Maximum Fair Price for Xolair is scheduled to take effect January 1, 2028.
- Published cost-effectiveness analyses of comparators report ICERs for omalizumab of £27,469 per QALY gained (NICE TA339, with the patient access scheme), £3183 (UK societal, Novartis-funded), €17 502 per QALY gained (Netherlands societal), and ¥160,411/QALY (China, patient perspective); a US poster reports $3,208,966 per QALY over 10 years for remibrutinib with cetirizine. NICE draft guidance of September 2026 states that remibrutinib should not be used for CSU inadequately controlled by H1-antihistamines in adults. No dupilumab cost-effectiveness analysis in CSU was found.
- The UK omalizumab model assigns utilities from 0.712 for UAS7 = 28–42 to 0.897 for UAS7 = 0.
- Celldex states a prevalence of 0.5-1.0% of the total population, or up to approximately 1 to 3 million patients in the United States.

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm); [Novartis Rhapsido savings and support page (2026)](https://www.rhapsido.com/savings-support); [Regeneron Dupixent Colorado price disclosure (2026)](https://www.regeneron.com/downloads/codrugcosteducation_dupixent.pdf); [Genentech Xolair cost page (2026)](https://www.xolair.com/cost.html); [Oregon PDAB Xolair affordability review (2026)](https://dfr.oregon.gov/pdab/Documents/Xolair-2026.pdf); [NICE TA339 (2015)](https://www.nice.org.uk/guidance/ta339/resources/omalizumab-for-previously-treated-chronic-spontaneous-urticaria-pdf-82602555773893); [Graham et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4929169/); [Kanters et al. (2018)](https://doi.org/10.1111/bjd.16476); [Huang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12285021/); [Jang and Lee (2026)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2026/poster-session-3-3/cost-effectiveness-of-remibrutinib-for-moderate-to-severe-chronic-spontaneous-urticaria-in-the-u-s); [NICE remibrutinib draft guidance (2026)](https://www.nice.org.uk/guidance/gid-ta11416/documents/draft-guidance)

<a id="topic-4.1-2"></a>

### Remibrutinib list price per 30-day supply, January 2026

> “The list (or wholesale) price for RHAPSIDO, as of January 7, 2026, is $4,521 per package (30-day supply, 60 tablets).”

Source: [Novartis Rhapsido savings and support page (2026)](https://www.rhapsido.com/savings-support)

<a id="topic-4.1-3"></a>

### Dupilumab wholesale acquisition cost per 4-week supply, January 2026

> “$4,193.03 per 4-week supply”
> “A four-week supply of DUPIXENT (200mg or 300 mg) is defined as two injections.”
> “Pricing as of January 1, 2026.”

Source: [Regeneron Dupixent Colorado price disclosure (2026)](https://www.regeneron.com/downloads/codrugcosteducation_dupixent.pdf)

<a id="topic-4.1-4"></a>

### Omalizumab annual list price range

> “The current list price* of XOLAIR is approximately $30,000 - $60,000 annually, but most people will not pay this amount.”
> “Current list price refers to the wholesale acquisition cost (WAC).”

Source: [Genentech Xolair cost page (2026)](https://www.xolair.com/cost.html)

<a id="topic-4.1-5"></a>

### Omalizumab unit wholesale acquisition cost at the end of 2025 and annual increase since 2019

> “The WAC of Xolair was approximately $1472.76 per unit at the end of 2025.”
> “Between 2019-2025, the unit WAC increased at an average annual rate of 4.9 percent”

Source: [Oregon PDAB Xolair affordability review (2026)](https://dfr.oregon.gov/pdab/Documents/Xolair-2026.pdf)

<a id="topic-4.1-6"></a>

### Wholesale acquisition cost per 30-day supply of omalizumab and dupilumab in 2025

| Product | Quoted dosage and frequency | Quoted year | Quoted WAC per 30-day supply |
| --- | --- | --- | --- |
| Omalizumab (Xolair) | “600 mg every 1 month” | “2025” | “$5,891” |
| Dupilumab (Dupixent) | “300 mg every 2 weeks” | “2025” | “$3,993” |

Source: [Oregon PDAB Xolair affordability review (2026)](https://dfr.oregon.gov/pdab/Documents/Xolair-2026.pdf)

<a id="topic-4.1-7"></a>

### Omalizumab biosimilar competition and Medicare price negotiation

> “biosimilar competition became available in 2026, which may affect future pricing and market competition despite remaining patents. Xolair was also selected for the third cycle of the Medicare Drug Price Negotiation Program, with any negotiated Maximum Fair Price scheduled to take effect January 1, 2028.”

Source: [Oregon PDAB Xolair affordability review (2026)](https://dfr.oregon.gov/pdab/Documents/Xolair-2026.pdf)

> “The Xolair/omalizumab biosimilar Omlyclo, FDA approved for the treatment of four allergic and inflammatory conditions, is commercially available in the U.S., according to a press release.”

Source: [Healio (2026)](https://www.healio.com/news/allergy-asthma/20261020/xolair-biosimilar-omlyclo-commercially-available-in-us)

<a id="topic-4.1-8"></a>

### Omalizumab: UK list price and company ICERs with the patient access scheme

> “Omalizumab costs £256.15 for a 150 mg prefilled syringe (excluding VAT; BNF online October 2014). A single dose of 300 mg costs £512.30 and the cost for a 24-week course of treatment is £3,073.80 (excluding VAT).”
> “This resulted in an incremental cost-effectiveness ratio (ICER) of £19,632 per QALY gained.”
> “The company's revised deterministic base-case result showed that, with the patient access scheme, omalizumab was associated with a total incremental cost of £7,222 with an additional gain of 0.263 QALYs, which resulted in an ICER of £27,469 per QALY gained.”
> “The probabilistic analysis indicated that there is a 0.2% and 80.7% probability of omalizumab being cost effective, at the maximum acceptable ICERs of £20,000 and £30,000 per QALY gained respectively.”
> “The Committee noted that, for patients with severe disease at baseline, the revised base-case ICER was lower than that for the combined (moderate and severe) disease and was around £26,000 per QALY gained.”

Source: [NICE TA339 (2015)](https://www.nice.org.uk/guidance/ta339/resources/omalizumab-for-previously-treated-chronic-spontaneous-urticaria-pdf-82602555773893)

<a id="topic-4.1-9"></a>

### Omalizumab: recommendation restricted to severe CSU with a stopping rule

> “Omalizumab is recommended as an option as add-on therapy for treating severe chronic spontaneous urticaria in adults and young people aged 12 years and over only if:”
> “the severity of the condition is assessed objectively, for example, using a weekly urticaria activity score of 28 or more”
> “omalizumab is stopped at or before the fourth dose if the condition has not responded”

Source: [NICE TA339 (2015)](https://www.nice.org.uk/guidance/ta339/resources/omalizumab-for-previously-treated-chronic-spontaneous-urticaria-pdf-82602555773893)

<a id="topic-4.1-10"></a>

### Omalizumab versus standard of care: UK societal cost-utility model, Novartis-funded

> “The aim of this study was to assess the cost utility of add-on omalizumab treatment compared with standard of care (SOC) in moderate or severe CSU patients with inadequate response to SOC, from the UK societal perspective.”
> “Model cycle length was 4 weeks, and total model time horizon was 20 years in the base case.”
> “With a deterministic ICER of £3183 in the base case, omalizumab was associated with increased costs and benefits relative to SOC. Probabilistic sensitivity analysis supported this result. Productivity inputs were key model drivers”
> “This research was funded by Novartis.”

Source: [Graham et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4929169/)

<a id="topic-4.1-11"></a>

### Health-state utilities by UAS7 band in the UK omalizumab model

| Health state | Quoted UAS7 band | Quoted utility value (SD; distribution) |
| --- | --- | --- |
| Severe urticaria | “UAS7 = 28–42” | “0.712 (0.31; Beta)” |
| Moderate urticaria | “UAS7 = 16–27” | “0.782 (0.26; Beta)” |
| Mild urticaria | “UAS7 = 7–15” | “0.845 (0.24; Beta)” |
| Well-controlled urticaria | “UAS7 = 1–6” | “0.859 (0.24; Beta)” |
| Urticaria-free | “UAS7 = 0” | “0.897 (0.25; Beta)” |

Source: [Graham et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4929169/)

<a id="topic-4.1-12"></a>

### Omalizumab versus standard of care: Netherlands societal perspective

> “in the Netherlands from a societal perspective.”
> “The incremental cost-effectiveness ratio (ICER) of omalizumab vs. SoC was €17 502 per quality-adjusted life-year (QALY) gained. Productivity costs played an important role in the value of the ICER; discarding productivity costs resulted in an ICER of €85 310 per QALY.”
> “Omalizumab is cost-effective compared with SoC.”

Source: [Kanters et al. (2018)](https://doi.org/10.1111/bjd.16476)

<a id="topic-4.1-13"></a>

### Omalizumab versus standard treatment: China, patient perspective

> “However, the economics of omalizumab treatment relative to standard therapies remains unknown in China.”
> “The ICER of omalizumab treatment relative to standard treatment was ¥160,411/QALY, which was between 1 and 3 times GDP per capita.”
> “The purpose of this study was to analyze the cost-effectiveness of omalizumab versus standard treatments for CSU after omalizumab’s inclusion in the National Drug Insurance List from the patient’s perspective.”

Source: [Huang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12285021/)

<a id="topic-4.1-14"></a>

### Remibrutinib with cetirizine versus cetirizine alone: US healthcare sector model

> “This study aims to evaluate the cost-effectiveness of remibrutinib compared to the standard of care (SOC) second-generation antihistamine from a healthcare sector perspective in the U.S.”
> “We constructed a Markov model to estimate 10-year and 24-week outcomes among patients with moderate to severe CSU, with the interventions being either remibrutinib with cetirizine or cetirizine alone.”
> “The ICER of the 10-year time horizon was $3,208,966 per QALY, and the ICER of the 24-week time horizon was $232,084 per QALY. Based on a WTP of $150,000 per QALY, remibrutinib was not cost-effective.”

Source: [Jang and Lee (2026)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2026/poster-session-3-3/cost-effectiveness-of-remibrutinib-for-moderate-to-severe-chronic-spontaneous-urticaria-in-the-u-s)

<a id="topic-4.1-15"></a>

### Remibrutinib: NICE draft guidance, September 2026

> “These are NICE’s draft recommendations.”
> “Remibrutinib should not be used to treat chronic spontaneous urticaria (CSU) inadequately controlled by H1-antihistamines in adults.”
> “There are no direct or indirect comparisons comparing remibrutinib with any of the usual treatments.”
> “Because of the uncertainties with the comparative clinical-effectiveness evidence and the long-term assumptions in the economic model, it is not possible to determine the most likely cost-effectiveness estimates for remibrutinib.”
> “The list price of remibrutinib in the company submission is confidential.”
> “Issue date: September 2026”

Source: [NICE remibrutinib draft guidance (2026)](https://www.nice.org.uk/guidance/gid-ta11416/documents/draft-guidance)

<a id="topic-4.1-16"></a>

### Remibrutinib coverage and workplace productivity: Canadian prevalence-based model

> “The objectives of this study are to estimate annual productivity burden among employed Canadians with symptomatic CSU despite H1-AHs, and benefits with remibrutinib coverage.”
> “A static, prevalence-based model estimated annual workdays lost (absenteeism, short-term disability) and reduced productivity (presenteeism) in people with CSU.”
> “Symptomatic CSU despite H1-AH treatment is estimated to account for 892,029 lost workdays and 4.8 million days of reduced-productivity annually, corresponding to 24 lost workdays and 130 days of reduced-productivity workdays per treated worker.”
> “Introducing remibrutinib coverage is expected to reduce productivity burden by 69% overall, supporting the economic value of remibrutinib for employers and private payers.”

Source: [Mtibaa et al. (2026)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2026/poster-session-3-4/impact-of-remibrutinib-treatment-on-workplace-productivity-due-to-chronic-spontaneous-urticaria-csu--a-canadian-private-payor-perspective)

<a id="topic-4.1-17"></a>

### Dupilumab cost-effectiveness analysis in CSU

No evidence found.

<a id="topic-4.1-18"></a>

### Routine laboratory screening versus no testing in adults with CSU: Markov cost-effectiveness model

> “A Markov model using cohort analysis and microsimulations was created for adult patients aged 20 years, over a 10-year time horizon, randomized to receive screening laboratory testing or a no-testing approach.”
> “Screening tests were not cost-effective, with ICERs of $856,905 (no therapy), $855,764 (antihistamine therapy), $847,483 (cyclosporine), and $627,318 (omalizumab).”

Source: [Shaker et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31751758/)

<a id="topic-4.1-19"></a>

### Omalizumab biosimilar: budget impact model across 23 European countries

> “A biosimilar market share uptake-based budget impact model (BIM) was developed in Microsoft Excel to compare two scenarios over 5 years: one without biosimilar introduction and one with gradual adoption.”
> “Omalizumab, a monoclonal antibody indicated for severe persistent allergic asthma, chronic spontaneous urticaria (CSU), and chronic rhinosinusitis with nasal polyps (CRSwNP), imposes a financial burden on European healthcare systems due to its high cost, with expenditures exceeding €787 million across 23 countries in 2024.”
> “Introducing an omalizumab biosimilar is projected to save €40 million in the first year at a 30% discounted price compared with using only the originator across 23 countries.”

Source: [Jang et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40955168/)

<a id="topic-4.1-20"></a>

### Company statement of CSU prevalence and US patient numbers

> “It is one of the most frequent dermatologic diseases with a prevalence of 0.5-1.0% of the total population or up to approximately 1 to 3 million patients in the United States”
> “Approximately 50% of patients with CSU achieve symptomatic control with antihistamines.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-4.1-21"></a>

### Company statements on the second-line advanced therapy market, angioedema, and severe disease

> “2L advanced therapy market projected to eclipse 1L market, consistent with other I&I chronic disease markets”
> “55% of patients with CSU experience angioedema”
> “25-35% of patients with CSU assessed as severe”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
